Regulatory T, natural killer T and γδ T cells in multiple sclerosis and chronic fatigue syndrome/myalgic encephalomyelitis: a comparison.
Ramos, Sandra, Brenu, Ekua, Broadley, Simon et al. · Asian Pacific journal of allergy and immunology · 2016 · DOI
Quick Summary
This study compared immune system cells in people with ME/CFS, people with multiple sclerosis (MS), and healthy people. Researchers found that ME/CFS patients had higher levels of certain regulatory immune cells called Tregs, while MS patients had lower levels of gamma delta T cells. The findings suggest that ME/CFS and MS affect the immune system in different ways, rather than through the same mechanisms.
Why It Matters
This study provides evidence that ME/CFS involves specific immune dysregulation distinct from other conditions like MS, which may eventually help clarify the biological basis of ME/CFS. Understanding these immune differences could lead to better diagnostic approaches and targeted treatments specific to ME/CFS rather than applying MS-based interventions.
Observed Findings
Significantly increased regulatory T cells (Tregs) in ME/CFS patients compared to healthy controls (p≤0.05)
Significantly increased CD4+ iNKT cell percentage in ME/CFS patients compared to healthy controls and MS patients
Significantly decreased double-negative iNKT cell percentage in ME/CFS patients compared to healthy controls
Significantly reduced total γδ and γδ2 T cells in MS patients compared to healthy controls
No immune cell abnormalities shared between ME/CFS and MS groups
Inferred Conclusions
ME/CFS and MS involve different immunological dysregulation pathways rather than shared mechanisms
Elevated Tregs in ME/CFS may reflect a distinct pattern of immune regulation
The differential immune profiles between conditions suggest condition-specific disease mechanisms requiring separate investigative approaches
Remaining Questions
How do these immune cell abnormalities relate to ME/CFS symptom severity and patient outcomes?
Are these immune differences stable over time or do they fluctuate with disease activity?
What functional consequences do elevated Tregs and altered iNKT cells have in ME/CFS pathogenesis?
What This Study Does Not Prove
This cross-sectional study cannot establish causation—it shows associations at a single time point but does not prove these immune changes cause ME/CFS symptoms. The small sample size (24 ME/CFS patients) limits generalizability, and the study does not explain how these cell differences relate to disease severity or patient outcomes. Findings require validation in larger, longitudinal studies.